NYSE:LLYEli Lilly And Co Stock Price, Forecast & News

$151.16

-1.12 (-0.74 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$150.17

Now: $151.16▼

$152.56

50-Day Range

$136.42

MA: $152.85▼

$162.93

52-Week Range

$101.36

Now: $151.16▼

$164.90

Volume2.35 million shs

Average Volume2.88 million shs

Market Capitalization$144.58 billion

P/E Ratio24.99

Dividend Yield1.96%

Beta0.25

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of rheumatoid arthritis and plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; AC Immune SA; and Avidity Biosciences, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Beat the Market (BTM) Rank^™

2.4 Analyst's Opinion

Consensus Rating
Eli Lilly And Co has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $158.90, Eli Lilly And Co has a potential upside of 5.1% from its current price of $151.16.
Amount of Analyst Coverage
Eli Lilly And Co has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Eli Lilly And Co has received 1,005 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eli Lilly And Co has received 828 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eli Lilly And Co has received 54.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote “Outperform” if you believe LLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
Eli Lilly And Co is a leading dividend payer. It pays a dividend yield of 1.96%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Eli Lilly And Co has been increasing its dividend for 5 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly And Co is 49.01 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly And Co will have a dividend payout ratio of 36.91 % next year. This indicates that Eli Lilly And Co will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly And Co insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,984,238.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Eli Lilly And Co is held by insiders.
Percentage Held by Institutions
77.98% of the stock of Eli Lilly And Co is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly And Co are expected to grow by 17.77% in the coming year, from $6.81 to $8.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly And Co is 24.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly And Co is 24.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.37.
Price to Earnings Growth Ratio
Eli Lilly And Co has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly And Co has a P/B Ratio of 45.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:LLY

Previous Symbol

CUSIP53245710

CIK59478

Webwww.lilly.com

Phone317-276-2000

Debt

Debt-to-Equity Ratio4.37

Current Ratio1.11

Quick Ratio0.86

Price-To-Earnings

Trailing P/E Ratio24.99

Forward P/E Ratio22.20

P/E Growth1.81

Sales & Book Value

Annual Sales$22.32 billion

Price / Sales6.48

Cash Flow$7.08 per share

Price / Cash Flow21.34

Book Value$3.34 per share

Price / Book45.26

Profitability

EPS (Most Recent Fiscal Year)$6.04

Net Income$8.32 billion

Net Margins23.97%

Return on Equity194.18%

Return on Assets15.11%

Miscellaneous

Employees33,625

Outstanding Shares956,450,000

Market Cap$144.58 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

How has Eli Lilly And Co's stock been impacted by COVID-19 (Coronavirus)?

Eli Lilly And Co's stock was trading at $140.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LLY stock has increased by 8.0% and is now trading at $151.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eli Lilly And Co?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eli Lilly And Co.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Eli Lilly And Co.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) announced its quarterly earnings results on Thursday, April, 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.27. The business earned $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The firm's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the business posted $1.33 EPS. View Eli Lilly And Co's earnings history.

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co declared a quarterly dividend on Monday, May 4th. Shareholders of record on Friday, May 15th will be given a dividend of $0.74 per share on Wednesday, June 10th. This represents a $2.96 dividend on an annualized basis and a yield of 1.96%. The ex-dividend date of this dividend is Thursday, May 14th. View Eli Lilly And Co's dividend history.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co issued an update on its FY20 earnings guidance on Thursday, April, 23rd. The company provided earnings per share (EPS) guidance of $6.70-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.68. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.73 billion.

What price target have analysts set for LLY?

11 Wall Street analysts have issued 12 month price targets for Eli Lilly And Co's stock. Their forecasts range from $133.00 to $185.00. On average, they anticipate Eli Lilly And Co's stock price to reach $158.90 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price. View analysts' price targets for Eli Lilly And Co.

Has Eli Lilly And Co been receiving favorable news coverage?

News coverage about LLY stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutEli Lilly And Co.

Are investors shorting Eli Lilly And Co?

Eli Lilly And Co saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 8,660,000 shares, a decline of 9.5% from the April 30th total of 9,570,000 shares. Based on an average daily volume of 4,680,000 shares, the short-interest ratio is currently 1.9 days. Currently, 1.0% of the shares of the company are sold short. View Eli Lilly And Co's Current Options Chain.

Who are some of Eli Lilly And Co's key competitors?

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

What other stocks do shareholders of Eli Lilly And Co own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and AT&T (T).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the following people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.84%), BlackRock Inc. (6.72%), Primecap Management Co. CA (4.38%), State Street Corp (3.87%), Wellington Management Group LLP (3.77%) and Capital International Investors (2.38%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, Daniel Skovronsky, David A Ricks, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry. View institutional ownership trends for Eli Lilly And Co.

Which major investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Capital International Investors, Franklin Resources Inc., Lilly Endowment Inc., Primecap Management Co. CA, Alliancebernstein L.P., AQR Capital Management LLC, and Deutsche Bank AG. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Michael J Harrington, Myles O'neill, and Stephen F Fry. View insider buying and selling activity for Eli Lilly And Co.

Which major investors are buying Eli Lilly And Co stock?

LLY stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., APG Asset Management N.V., Capital World Investors, Nuveen Asset Management LLC, 1832 Asset Management L.P., APG Asset Management N.V., and APG Asset Management N.V.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Anne E White, Daniel Skovronsky, David A Ricks, Jackson P Tai, and Joshua L Smiley. View insider buying and selling activity for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $151.16.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $144.58 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly And Co employs 33,625 workers across the globe.

What is Eli Lilly And Co's official website?

The official website for Eli Lilly And Co is www.lilly.com.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff